Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment of growth hormone deficiency in children

Alan D Rogol, MD, PhD
Section Editor
Mitchell Geffner, MD
Deputy Editor
Alison G Hoppin, MD


The importance of the pituitary gland for growth was recognized in 1886, when Marie noted the association between pituitary tumors and symptoms and signs of acromegaly [1]. The presence of a growth-promoting factor in the hypophysis was demonstrated in 1909, when Aschner demonstrated that removal of the pituitary from puppies causes severe growth retardation [2].

It was not until 1921, however, that a positive effect of the hypophysis on growth was demonstrated by studies in which intraperitoneal administration of a saline extract of anterior pituitary lobes was found to increase body weight in rats [3]. In a classic series of experiments in 1930, the necessity for the hypophysis for normal growth was conclusively demonstrated [4]. Ablation of the hypophysis resulted in the cessation of growth, which was restored by anterior pituitary lobe transplants. When injected intraperitoneally, a saline suspension of anterior lobes stimulated growth in hypophysectomized rats but had no effect on the atrophied reproductive organs.

The indications for and efficacy of exogenous growth hormone treatment in children with growth hormone deficiency are reviewed here. The diagnostic approach to the child with short stature and the diagnosis of growth hormone deficiency are discussed separately. (See "Causes of short stature" and "Diagnostic approach to children and adolescents with short stature" and "Diagnosis of growth hormone deficiency in children".)

Growth hormone therapy is also prescribed for several other specific indications in children and adolescents; these uses are discussed in separate topic reviews:

Growth failure associated with chronic kidney disease. (See "Growth hormone treatment in children with chronic kidney disease and postrenal transplantation".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jun 29, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Marie P. Hypertrophie singuliére non congénitale des extrémités supérieures, inférieures et céphaliques. Rev Med 1886; 6:297.
  2. Aschner B. Demonstration von Hunden nach Exirpation der Hypohyse. Wien Klin Wochenschr 1909; 22:1730.
  3. Evans HE, Long JA. The effect of the anterior lobe administered intraperitoneally upon growth, maturity and oestrus cycles of the rat. Anat Rec 1921; 21:62.
  4. Smith PE. Hypophysectomy and replacement therapy in the rat. Am J Anat 1930; 45:205.
  5. MURPHY WR, DAUGHADAY WH, HARTNETT C. The effect of hypophysectomy and growth hormone on the incorporation of labeled sulfate into tibial epiphyseal and nasal cartilage of the rat. J Lab Clin Med 1956; 47:715.
  6. SALMON WD Jr, DAUGHADAY WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49:825.
  7. Kaplan SA, Cohen P. The somatomedin hypothesis 2007: 50 years later. J Clin Endocrinol Metab 2007; 92:4529.
  8. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995; 80:1532.
  9. de Muinck Keizer-Schrama SM, Rikken B, Wynne HJ, et al. Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: effects on auxological and biochemical parameters. Dutch Growth Hormone Working Group. J Clin Endocrinol Metab 1992; 74:898.
  10. Blethen SL, Compton P, Lippe BM, et al. Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J Clin Endocrinol Metab 1993; 76:574.
  11. Albertsson-Wikland K. The effect of human growth hormone injection frequency on linear growth rate. Acta Paediatr Scand Suppl 1987; 337:110.
  12. MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group. J Clin Endocrinol Metab 1996; 81:1806.
  13. Peter F, Savoy C, Ji HJ, et al. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. Eur J Endocrinol 2009; 160:349.
  14. Péter F, Bidlingmaier M, Savoy C, et al. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J Clin Endocrinol Metab 2012; 97:400.
  15. Khadilkar V, Radjuk KA, Bolshova E, et al. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency. J Clin Endocrinol Metab 2014; 99:126.
  16. Cohen P, Germak J, Rogol AD, et al. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab 2010; 95:2089.
  17. Cohen P, Weng W, Rogol AD, et al. Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations. Clin Endocrinol (Oxf) 2014; 81:71.
  18. Ranke MB, Lindberg A, KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010; 95:1229.
  19. Bakker B, Frane J, Anhalt H, et al. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 2008; 93:352.
  20. Kemp SF. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options. BioDrugs 2009; 23:155.
  21. Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92:902.
  22. Root AW, Kemp SF, Rundle AC, et al. Effect of long-term recombinant growth hormone therapy in children--the National Cooperative Growth Study, USA, 1985-1994. J Pediatr Endocrinol Metab 1998; 11:403.
  23. Reiter EO, Price DA, Wilton P, et al. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006; 91:2047.
  24. Frasier SD, Costin G, Lippe BM, et al. A dose-response curve for human growth hormone. J Clin Endocrinol Metab 1981; 53:1213.
  25. Ranke MB, Lindberg A, Chatelain P, et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999; 84:1174.
  26. Zadik Z, Sinai T, Zung A, Reifen R. Effect of nutrition on growth in short stature before and during growth-hormone therapy. Pediatrics 2005; 116:68.
  27. Gharib H, Cook DM, Saenger PH, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children--2003 update. Endocr Pract 2003; 9:64.
  28. Mauras N, Attie KM, Reiter EO, et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab 2000; 85:3653.
  29. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123:e752.
  30. Mericq MV, Eggers M, Avila A, et al. Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 2000; 85:569.
  31. Saggese G, Federico G, Barsanti S, Fiore L. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study. J Clin Endocrinol Metab 2001; 86:1900.
  32. Lee PA. Use of GnRH agonists in GH-deficient patients: arguments for and against. The case for GnRH agonists in GH-deficient patients. Pediatr Endocrinol Rev 2008; 5 Suppl 2:744.
  33. Reiter EO. A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: Previously published studies from America. Mol Cell Endocrinol 2006; 254-255:221.
  34. Mauras N, Welch S, Rini A, Klein KO. An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 2004; 17:1597.
  35. Wickman S, Sipilä I, Ankarberg-Lindgren C, et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001; 357:1743.
  36. Kreher NC, Eugster EA, Shankar RR. The use of tamoxifen to improve height potential in short pubertal boys. Pediatrics 2005; 116:1513.
  37. Mauras N, Gonzalez de Pijem L, Hsiang HY, et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008; 93:823.
  38. Geffner ME. Aromatase inhibitors to augment height: continued caution and study required. J Clin Res Pediatr Endocrinol 2009; 1:256.
  39. Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model. J Clin Invest 1994; 93:799.
  40. Saggese G, Baroncelli GI, Bertelloni S, Barsanti S. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab 1996; 81:3077.
  41. Bonjour JP, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73:555.
  42. de Boer H, Blok GJ, van Lingen A, et al. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994; 9:1319.
  43. Holmes SJ, Economou G, Whitehouse RW, et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78:669.
  44. Conway GS, Szarras-Czapnik M, Racz K, et al. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol 2009; 160:899.
  45. Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81:1704.
  46. Saenger P, Attie KM, DiMartino-Nardi J, et al. Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Study Group. J Clin Endocrinol Metab 1998; 83:3115.
  47. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001; 86:1868.
  48. Youngster I, Rachmiel R, Pinhas-Hamiel O, et al. Treatment with recombinant human growth hormone during childhood is associated with increased intraocular pressure. J Pediatr 2012; 161:1116.
  49. Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res 2007; 68 Suppl 5:41.
  50. Bourguignon JP, Piérard GE, Ernould C, et al. Effects of human growth hormone therapy on melanocytic naevi. Lancet 1993; 341:1505.
  51. Hansen TK, Møller J, Thomsen K, et al. Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 2001; 281:E1326.
  52. Pitukcheewanont P, Schwarzbach L, Kaufman FR. Resumption of growth after methionyl-free human growth hormone therapy in a patient with neutralizing antibodies to methionyl human growth hormone. J Pediatr Endocrinol Metab 2002; 15:653.
  53. Meazza C, Schaab M, Pagani S, et al. Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report. J Pediatr Endocrinol Metab 2013; 26:785.
  54. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000; 355:610.
  55. Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. Lancet 2002; 360:268.
  56. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002; 360:273.
  57. Wilton P, Mattsson AF, Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr 2010; 157:265.
  58. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol (Oxf) 2006; 64:115.
  59. Ross J, Czernichow P, Biller BM, et al. Growth hormone: health considerations beyond height gain. Pediatrics 2010; 125:e906.
  60. Banerjee I, Clayton PE. Growth hormone treatment and cancer risk. Endocrinol Metab Clin North Am 2007; 36:247.
  61. Raman S, Grimberg A, Waguespack SG, et al. Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee. J Clin Endocrinol Metab 2015; 100:2192.
  62. Fradkin JE, Mills JL, Schonberger LB, et al. Risk of leukemia after treatment with pituitary growth hormone. JAMA 1993; 270:2829.
  63. Nishi Y, Tanaka T, Takano K, et al. Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan. J Clin Endocrinol Metab 1999; 84:1961.
  64. Allen DB, Rundle AC, Graves DA, Blethen SL. Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr 1997; 131:S32.
  65. Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000; 85:4444.
  66. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002; 87:3136.
  67. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91:3494.
  68. Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012; 97:416.
  69. 12/22/10: FDA Drug Safety Communication: Safety review update of recombinant human growth hormone (somatropin) and possible increased risk of death. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm265865.htm.
  70. Sävendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012; 97:E213.
  71. Poidvin A, Touzé E, Ecosse E, et al. Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology 2014; 83:780.
  72. 8/25/14: Endocrine Society statement on possible association between GH therapy in childhood and later stroke. Available at: https://www.endocrine.org/~/media/endosociety/Files/Advocacy%20and%20Outreach/Position%20Statements/Other%20Statements/GH%20Stroke%20Statement%20Final%20on%20letterhead.pdf (Accessed on September 08, 2014).
  73. Frasier SD. The not-so-good old days: working with pituitary growth hormone in North America, 1956 to 1985. J Pediatr 1997; 131:S1.
  74. Wacharasindhu S, Cotterill AM, Camacho-Hübner C, et al. Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth. Clin Endocrinol (Oxf) 1996; 45:553.
  75. Tauber M, Moulin P, Pienkowski C, et al. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J Clin Endocrinol Metab 1997; 82:352.
  76. Zucchini S, Pirazzoli P, Baronio F, et al. Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency. J Clin Endocrinol Metab 2006; 91:4271.
  77. Ho KK, 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007; 157:695.